The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The FDA Approved Several New Rheumatology Drugs in 2017

The FDA Approved Several New Rheumatology Drugs in 2017

March 18, 2018 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF
PhuShutter / shutterstock.com

PhuShutter / shutterstock.com

SAN DIEGO—In a session at the 2017 ACR/ARHP Annual Meeting, Kam Nola, PharmD, MS, professor in the College of Pharmacy and vice chair in the Department of Pharmacy Practice at Lipscomb University in Nashville, Tenn., updated participants on new medications and new indications for rheumatology treatments and safety labeling changes approved by the U.S. Food and Drug Administration (FDA) over the past year. “One theme is incorporation of more new data from trials into labeling,” she said.

You Might Also Like
  • Etanercept Biosimilar Approved in EU, Plus FDA Reviews Brodalumab for Plaque Psoriasis
  • First Biosimilar Drugs Approved in U.S., Canada
  • The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk
Explore This Issue
March 2018

An important new development is approval of the first oral solution of methotrexate for patients with polyarticular juvenile idiopathic arthritis, she said. In May, the first FDA-approved therapy specifically for giant cell arteritis (GCA) was announced. “This is great news for GCA patients,” Dr. Nola said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In an expansion of labeling, tocilizumab was approved as an intravenous dose for cancer patients receiving chimeric antigen receptor (CAR) T cell therapy and experiencing severe or life-threatening cytokine release syndrome.

Brodalumab, an interleukin (IL) 17 inhibitor, was approved in February in a prefilled, single-dose, subcutaneous syringe for moderate to severe plaque psoriasis. It is contraindicated for Crohn’s disease, and it comes with a significant warning for adverse events, such as suicidal ideation. Dispensing requires the provider’s enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program mandated by the FDA to ensure that patients, care­givers and providers are aware of the risks. Patients get a wallet card with information about risk.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Have a conversation with your patients. Make sure they know that if they have [suicidal] thoughts, they need to talk to someone as soon as possible,” Dr. Nola said.

Other FDA approvals significant for rheumatology include:

  • Abaloparatide, a human parathyroid hormone-related peptide analog was approved in April for post-menopausal women with osteoporosis and a high risk for fracture;
  • Sarilumab, a new IL-6 receptor antagonist for patients with moderate to severe rheumatoid arthritis who have not responded well to one or more disease-modifying anti-rheumatic drugs (DMARDs), was approved in May. It can be prescribed as monotherapy or in combination with methotrexate or other conventional DMARDs;
  • Guselkumab, an IL-23 blocker for severe plaque psoriasis, was approved in July, with a few warnings and precautions, mostly around infections. “Remember, infections are something we can’t overlook,” Dr. Nola said;
  • Belimumab in a new self-injectable form for lupus patients was approved in July; and
  • A fixed-dose combination of lesinurad and allopurinal was approved for the treatment of hyperuricemia in patients with gout who have not reached serum uric acid treatment targets on allopurinol alone. Considerations include how to set doses for the combination product for patients who are already receiving allopurinol.

In the world of biosimilars, a number of products have been approved by the FDA, and a number of others are in the pipeline. “The hot questions at this conference have been: ‘Are you using them yet? What are you doing with them?’” Dr. Nola observed. She expects news of more approvals in the near future for biosimilars for oncology and rheumatology drugs, such as filgrastim, bevacizumab, trastuzumab and rituximab, among others.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Larry Beresford is a freelance medical journalist in Oakland, Calif.

Editor’s note: The ACR recently released a white paper on biosimilars.

Pages: 1 2 | Multi-Page

Filed Under: Drug Updates, Meeting Reports Tagged With: abaloparatide, ACR/ARHP Annual Meeting, allopurinal, belimumab, brodalumab, guselkumab, lesinurad, Methotrexate, sarilumab, tocilizumabIssue: March 2018

You Might Also Like:
  • Etanercept Biosimilar Approved in EU, Plus FDA Reviews Brodalumab for Plaque Psoriasis
  • First Biosimilar Drugs Approved in U.S., Canada
  • The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk
  • FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)